Pliant Therapeutics Stock Equity Positions Weight

PLRX Stock

USD 1.49 0.06 3.87%

Pliant Therapeutics fundamentals help investors to digest information that contributes to Pliant Therapeutics' financial success or failures. It also enables traders to predict the movement of Pliant Stock. The fundamental analysis module provides a way to measure Pliant Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pliant Therapeutics stock.

Total Current Liabilities Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pliant Therapeutics Company Equity Positions Weight Analysis

Pliant Therapeutics' Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.

Stock Percentage

% of Equities

in the fund

More About Equity Positions Weight | All Equity Analysis

Pliant Equity Positions Weight Driver Correlations

Understanding the fundamental principles of building solid financial models for Pliant Therapeutics is extremely important. It helps to project a fair market value of Pliant Stock properly, considering its historical fundamentals such as Equity Positions Weight. Since Pliant Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pliant Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pliant Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Debt	Deferred Long Term Liab	Net Invested Capital	Capital Stock	Net Working Capital	Capital Surpluse	Short Term Debt	Long Term Debt	Long Term Debt Total
Total Assets		0.98	0.92	-0.83	0.74	0.55	0.47	1.0	0.95	0.59	0.61	0.88	0.98	-0.92	0.99	0.84	-0.58	0.45	-0.36
Total Stockholder Equity	0.98		0.93	-0.78	0.7	0.48	0.28	0.98	0.94	0.55	0.68	0.82	1.0	-0.93	0.99	0.8	-0.53	0.38	-0.31
Net Tangible Assets	0.92	0.93		-0.88	0.69	0.49	0.3	0.91	0.91	0.6	0.77	0.78	0.95	-0.98	0.92	0.79	-0.59	0.55	-0.58
Retained Earnings	-0.83	-0.78	-0.88		-0.84	-0.32	-0.52	-0.82	-0.89	-0.5	-0.59	-0.66	-0.81	0.8	-0.83	-0.88	0.82	-0.77	0.77
Accounts Payable	0.74	0.7	0.69	-0.84		0.2	0.46	0.73	0.83	0.49	0.39	0.57	0.72	-0.66	0.72	0.78	-0.83	0.78	-0.5
Net Receivables	0.55	0.48	0.49	-0.32	0.2		0.53	0.56	0.36	0.38	-0.01	0.75	0.49	-0.51	0.52	0.19	-0.23	0.19	-0.21
Total Liab	0.47	0.28	0.3	-0.52	0.46	0.53		0.45	0.42	0.4	-0.06	0.61	0.3	-0.27	0.37	0.46	-0.4	0.51	-0.38
Total Current Assets	1.0	0.98	0.91	-0.82	0.73	0.56	0.45		0.94	0.58	0.61	0.87	0.98	-0.91	0.99	0.82	-0.56	0.42	-0.35
Common Stock	0.95	0.94	0.91	-0.89	0.83	0.36	0.42	0.94		0.51	0.7	0.8	0.94	-0.88	0.94	0.95	-0.62	0.63	-0.42
Property Plant Equipment	0.59	0.55	0.6	-0.5	0.49	0.38	0.4	0.58	0.51		0.42	0.71	0.59	-0.72	0.52	0.31	-0.25	0.24	-0.27
Net Debt	0.61	0.68	0.77	-0.59	0.39	-0.01	-0.06	0.61	0.7	0.42		0.43	0.7	-0.77	0.62	0.67	-0.13	0.33	-0.32
Deferred Long Term Liab	0.88	0.82	0.78	-0.66	0.57	0.75	0.61	0.87	0.8	0.71	0.43		0.83	-0.83	0.83	0.65	-0.36	0.4	-0.25
Net Invested Capital	0.98	1.0	0.95	-0.81	0.72	0.49	0.3	0.98	0.94	0.59	0.7	0.83		-0.96	0.99	0.81	-0.55	0.42	-0.36
Capital Stock	-0.92	-0.93	-0.98	0.8	-0.66	-0.51	-0.27	-0.91	-0.88	-0.72	-0.77	-0.83	-0.96		-0.91	-0.71	0.49	-0.45	0.46
Net Working Capital	0.99	0.99	0.92	-0.83	0.72	0.52	0.37	0.99	0.94	0.52	0.62	0.83	0.99	-0.91		0.83	-0.6	0.42	-0.37
Capital Surpluse	0.84	0.8	0.79	-0.88	0.78	0.19	0.46	0.82	0.95	0.31	0.67	0.65	0.81	-0.71	0.83		-0.61	0.69	-0.46
Short Term Debt	-0.58	-0.53	-0.59	0.82	-0.83	-0.23	-0.4	-0.56	-0.62	-0.25	-0.13	-0.36	-0.55	0.49	-0.6	-0.61		-0.72	0.75
Long Term Debt	0.45	0.38	0.55	-0.77	0.78	0.19	0.51	0.42	0.63	0.24	0.33	0.4	0.42	-0.45	0.42	0.69	-0.72		-0.73
Long Term Debt Total	-0.36	-0.31	-0.58	0.77	-0.5	-0.21	-0.38	-0.35	-0.42	-0.27	-0.32	-0.25	-0.36	0.46	-0.37	-0.46	0.75	-0.73

Click cells to compare fundamentals

Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.

Competition

Predict Pliant Therapeutics

According to the company disclosure, Pliant Therapeutics has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Pliant Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Pliant Therapeutics from analyzing Pliant Therapeutics' financial statements. These drivers represent accounts that assess Pliant Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pliant Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	807.8M	483.9M	812.2M	1.1B	797.3M	509.1M
Enterprise Value	757.2M	439.5M	794.3M	1.0B	756.1M	473.5M

Pliant Fundamentals

	Return On Equity	-0.54
	Return On Asset	-0.31
	Current Valuation	(198.17 M)
	Shares Outstanding	61.24 M
	Shares Owned By Insiders	3.27 %
	Shares Owned By Institutions	96.73 %
	Number Of Shares Shorted	3.54 M
	Price To Book	0.32 X
	Price To Sales	3,072 X
	EBITDA	(228.37 M)
	Net Income	(210.3 M)
	Cash And Equivalents	163.6 M
	Cash Per Share	3.36 X
	Total Debt	29.98 M
	Debt To Equity	0.11 %
	Current Ratio	7.69 X
	Book Value Per Share	5.00 X
	Cash Flow From Operations	(155.5 M)
	Short Ratio	0.93 X
	Earnings Per Share	(3.47) X
	Target Price	10.06
	Number Of Employees	171
	Beta	1.19
	Market Capitalization	97.37 M
	Total Asset	396.95 M
	Retained Earnings	(710.05 M)
	Working Capital	329.05 M
	Net Asset	396.95 M

About Pliant Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pliant Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pliant Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pliant Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC